Scarica l'app Stockscreener
7.31
0.27%
0.02
Precedente Chiudi:
$7.29
Aprire:
$7.36
Volume 24 ore:
2.21M
Relative Volume:
0.76
Capitalizzazione di mercato:
$1.61B
Reddito:
$52.04M
Utile/perdita netta:
$-290.50M
Rapporto P/E:
-5.0216
EPS:
-1.4557
Flusso di cassa netto:
$-240.94M
1 W Prestazione:
+12.46%
1M Prestazione:
-4.69%
6M Prestazione:
-21.99%
1 anno Prestazione:
-38.16%
Intervallo 1D:
$0.00
$0.00
Intervallo di 1 settimana:
$6.40
$7.535
Portata 52W:
$6.00
$16.44
Ocular Therapeutix Inc Stock (OCUL) Company Profile
Nome
Ocular Therapeutix Inc
Settore
Industria
Telefono
781-357-4000
Indirizzo
14 CROSBY DRIVE, 3RD FLOOR, BEDFORD, MA
Compare OCUL vs VRTX, MRNA, REGN, ARGX, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
OCUL
Ocular Therapeutix Inc
|
7.31 | 1.61B | 52.04M | -290.50M | -240.94M | -1.4557 |
VRTX
Vertex Pharmaceuticals Inc
|
540.00 | 136.87B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
222.76 | 88.93B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
818.77 | 84.30B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
897.85 | 56.46B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
371.56 | 42.03B | 5.76B | 514.49M | 1.10B | 4.4813 |
Ocular Therapeutix Inc Stock (OCUL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-10-12 | Iniziato | UBS | Buy |
| 2025-09-15 | Iniziato | Chardan Capital Markets | Buy |
| 2025-04-08 | Iniziato | William Blair | Outperform |
| 2025-03-18 | Iniziato | RBC Capital Mkts | Outperform |
| 2025-03-11 | Iniziato | Needham | Buy |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-06-20 | Aggiornamento | TD Cowen | Hold → Buy |
| 2024-05-31 | Ripresa | Piper Sandler | Overweight |
| 2024-02-09 | Iniziato | BofA Securities | Buy |
| 2023-04-21 | Iniziato | Robert W. Baird | Outperform |
| 2022-08-10 | Ripresa | Berenberg | Buy |
| 2021-08-10 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-12-28 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2020-12-17 | Iniziato | Berenberg | Buy |
| 2020-11-13 | Reiterato | Raymond James | Strong Buy |
| 2020-08-10 | Reiterato | H.C. Wainwright | Buy |
| 2020-03-03 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2019-05-21 | Downgrade | Cowen | Outperform → Market Perform |
| 2019-05-21 | Reiterato | H.C. Wainwright | Buy |
| 2019-05-21 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2018-12-03 | Reiterato | Cantor Fitzgerald | Overweight |
| 2018-11-15 | Iniziato | Raymond James | Strong Buy |
| 2018-09-07 | Iniziato | Piper Jaffray | Overweight |
| 2017-10-24 | Iniziato | Guggenheim | Buy |
| 2017-07-26 | Iniziato | H.C. Wainwright | Buy |
| 2017-07-12 | Reiterato | Cantor Fitzgerald | Overweight |
| 2017-06-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2017-02-10 | Iniziato | Cantor Fitzgerald | Overweight |
| 2016-11-15 | Reiterato | RBC Capital Mkts | Outperform |
| 2016-08-11 | Iniziato | JMP Securities | Mkt Outperform |
| 2016-02-17 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2015-10-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2015-08-13 | Iniziato | Morgan Stanley | Overweight |
Mostra tutto
Ocular Therapeutix Inc Borsa (OCUL) Ultime notizie
Ocular Therapeutix™ to Participate in November Investor and Scientific Conferences - Yahoo! Finance Canada
Weekly Recap: AXPAXLI 505(b)(2) NDA filing and $600M cash runway - TradingView
Ocular Therapeutix: The Drug Won, The Stock Lost, And That's The Opportunity - Seeking Alpha
Ocular Therapeutix, Inc. Estimates – NASDAQ:OCUL - TradingView
Ocular Therapeutix at chardan healthcare conference: wet amd push advances - Investing.com Nigeria
Ocular Therapeutix Has 75% Success Probability for Axpaxli in Wet Age-Related Macular Degeneration, UBS Says - marketscreener.com
Ocular Therapeutix Eyes Q4 FDA Filing for AXPAXLI After SOL-1 Win - Yahoo Finance
Ocular Therapeutix Eyes Q4 FDA Filing for AXPAXLI After SOL-1 Win - TradingView
Ocular Therapeutix Eyes Q4 FDA Filing for AXPAXLI After SOL-1 Win - TradingView
Ocular Therapeutix at chardan healthcare conference: wet amd push advances - Investing.com
Ocular Therapeutix, Inc. (OCUL) options chain - Yahoo Finance Australia
Ocular Therapeutix stock hits 52-week low at 6.23 USD By Investing.com - Investing.com Nigeria
Ocular Therapeutix stock hits 52-week low at 6.23 USD By Investing.com - Investing.com South Africa
Ocular Therapeutix stock hits 52-week low at 6.23 USD - Investing.com
Novavax, Ocular Therapeutix, and QuidelOrtho Shares Plummet, What You Need To Know - Yahoo Finance
OCULAR THERAPEUTIX, INC. Announces Resignation of Sanjay Nayak as Chief Strategy Officer, Effective October 16, 2026 - www.marketscreener.com
Ocular Therapeutix, Inc. (OCUL) Presents at American Academy of Ophthalmology Retina Subspeciality DaySlideshow (NASDAQ:OCUL) 2026-10-15 - Seeking Alpha
Long term debt to total equity ratio of Ocular Therapeutix Inc – HAN:0OT - TradingView
Ocular Therapeutix CLO Todd Anderman sells $87,363 in company stock - Investing.com
Form 4 Ocular Therapeutix Inc: Todd Anderman (CLO) For: 8 October - Investing.com Nigeria
Form 4 Ocular Therapeutix Inc: Todd Anderman (CLO) For: 8 October - Investing.com India
To cover vesting taxes, Ocular Therapeutix (OCUL) legal chief sold 11,984 shares. - Stock Titan
Ocular Therapeutix Initiated at Buy by UBS - Moomoo
UBS Initiates Coverage on Ocular Therapeutix With Buy Rating, $14 Price Target - Moomoo
UBS initiates Ocular Therapeutix stock with buy rating on Axpaxli potential - Investing.com Canada
UBS initiates Ocular Therapeutix stock with buy rating on Axpaxli potential - Investing.com
Total debt per share of Ocular Therapeutix Inc – HAN:0OT - TradingView
OCUL Stock In Spotlight After Q2 Loss Comes In Narrower Than Estimated – A Look At Key Highlights - Stocktwits
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
15 new hires receive stock awards from Ocular Therapeutix - Stock Titan
Officer Todd Anderman proposes selling 11,984 shares of Ocular Therapeutix (OCUL). - Stock Titan
Form 4 Ocular Therapeutix Inc For: 6 October By Investing.com - Investing.com Nigeria
Ocular Therapeutix, Inc. (OCUL) Presents at Euretina 2026Slideshow (NASDAQ:OCUL) 2026-10-06 - Seeking Alpha
Ocular Therapeutix CDO Peter Kaiser sells $70,429 in stock - Investing.com
An automatic tax-related sale of 9,990 shares at Ocular Therapeutix (OCUL) was not discretionary. - Stock Titan
To cover taxes, Ocular Therapeutix (OCUL) officer Heier sold 10,869 shares under automatic instructions. - Stock Titan
After stock vesting, an officer proposes selling 9,990 Ocular Therapeutix (OCUL) shares. - Stock Titan
Officer Jeffrey S. Heier proposes selling 10,869 Ocular Therapeutix (Nasdaq: OCUL) shares. - Stock Titan
Ocular Therapeutix (NasdaqGM:OCUL) Stock Forecast & Analyst Predictions - Simply Wall Street
Ocular Therapeutix (OCUL) Stock Still Looks Pricey As 145% Gain Draws Scrutiny - Yahoo Finance
OCUL Stock On Track For Worst Week In 2.5 Years As Rivals Raise The Bar In Wet AMD - Yahoo Finance
Ocular Therapeutix™ to Participate in October Scientific and Investor Conferences - Yahoo Finance
A Phase 3 eye-treatment trial is set for an October results presentation - Stock Titan
Operating income of Ocular Therapeutix Inc – HAN:0OT - TradingView
RBC Capital reiterates Ocular Therapeutix stock rating on wAMD treatment potential - Investing.com Nigeria
ETFs Investing in Ocular Therapeutix Inc Stocks - TradingView
Ocular Therapeutix, Inc. (OCUL) Stock Price, News, Quote & History - Yahoo! Finance Canada
Precision Trading with Ocular Therapeutix Inc. (OCUL) Risk Zones - Stock Traders Daily
OCUL Stock Is Climbing Ahead Of Investor Day — What Is On The Agenda? - Stocktwits
Is Ocular Therapeutix (OCUL) Stock a Buy Ahead of Its Major NDA Catalyst? - AlphaStreet
Ocular Therapeutix Inc Azioni (OCUL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Ocular Therapeutix Inc Azioni (OCUL) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| TODD ANDERMAN | Officer |
Oct 08 '26 |
Proposed Sale |
7.29 |
11,984 |
87,315 |
0 |
| JEFFREY S. HEIER | Officer |
Oct 02 '26 |
Proposed Sale |
7.05 |
10,869 |
76,639 |
0 |
| Kaiser Peter | Chief Development Officer |
Oct 02 '26 |
Sale |
7.05 |
9,990 |
70,430 |
254,388 |
| PETER KAZUO KAISER | Officer |
Oct 02 '26 |
Proposed Sale |
7.05 |
9,990 |
70,459 |
0 |
| Heier Jeffrey S. | Chief Scientific Officer |
Oct 02 '26 |
Sale |
7.05 |
10,869 |
76,626 |
307,457 |
| DONALD D NOTMAN JR. | Officer |
Aug 31 '26 |
Proposed Sale |
10.24 |
1,099 |
11,252 |
0 |
| Notman Donald | Chief Operating Officer |
Aug 31 '26 |
Sale |
10.24 |
1,099 |
11,254 |
366,529 |
| PRAVIN DUGEL | Officer |
Aug 24 '26 |
Proposed Sale |
10.77 |
21,649 |
233,186 |
0 |
| JEFFREY S. HEIER | Officer |
Aug 24 '26 |
Proposed Sale |
10.78 |
3,296 |
35,532 |
0 |
| PETER KAZUO KAISER | Officer |
Aug 24 '26 |
Proposed Sale |
10.77 |
3,035 |
32,702 |
0 |
4.11%
2.14%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):